Proveca is a UK-based pharmaceutical company specialising in the design & licensing of medicines for children for a variety of therapy areas. Learn more.
Location: United Kingdom, England, Manchester
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | Albion Cap... | albion.cap... |
Mentions in press and media 6
| Date | Title | Description |
| 28.08.2026 | Second Quarter Report Q2-2026 | Second Quarter Report Q2-2026 Fri, Aug 28, 2026 08:30 CET Report this content Operational highlights Entered collaboration with Rigshospitalet to advance CT004 in paediatric patients Events after the reporting period CHMP opinion received f... |
| 03.08.2026 | Cessatech – EMA initial KemSu/CT001 opinion Q&A and next steps | Cessatech – EMA initial KemSu/CT001 opinion Q&A and next steps Mon, Aug 03, 2026 17:00 CET Report this content On 3 August – Cessatech A/S (“Cessatech” or “the Company”) releases a short Question and Answers (Q&A) overview, based on... |
| 24.07.2026 | Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu | Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu Fri, Jul 24, 2026 08:30 CET Report this content The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion... |
| 14.08.2025 | The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children | The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children Thu, Aug 14, 2025 18:00 CET Report this content Proveca has submitted a Paediatric Use Marketi... |
| 26.08.2024 | Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001 | Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001 Mon, Aug 26, 2024 08:30 CET Report this content Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excludi... |
| - | Albion Capital on the hunt for £80 million in new venture capital trust fundraise | London’s Albion Capital has announced its intention to raise £80 million with provisions for an additional £20 million in aggregate across its six funds. In total, these funds account for approximately £545 million in AUM. Focusing primaril... |